Cargando…

Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy

PURPOSE: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Alicia, Barsky, Andrew R., Maxwell, Russell, Bekelman, Justin E., Both, Stefan, Christodouleas, John P., Deville, Curtiland, Fang, Penny, Tochner, Zelig A., Vapiwala, Neha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Particle Therapy Co-operative Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009454/
https://www.ncbi.nlm.nih.gov/pubmed/35530185
http://dx.doi.org/10.14338/IJPT-21-00016
_version_ 1784687270803013632
author Bao, Alicia
Barsky, Andrew R.
Maxwell, Russell
Bekelman, Justin E.
Both, Stefan
Christodouleas, John P.
Deville, Curtiland
Fang, Penny
Tochner, Zelig A.
Vapiwala, Neha
author_facet Bao, Alicia
Barsky, Andrew R.
Maxwell, Russell
Bekelman, Justin E.
Both, Stefan
Christodouleas, John P.
Deville, Curtiland
Fang, Penny
Tochner, Zelig A.
Vapiwala, Neha
author_sort Bao, Alicia
collection PubMed
description PURPOSE: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment. METHODS: One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS. RESULTS: The median length of follow-up was 8.3 years (range, 1.2–10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P > .05). CONCLUSION: Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies.
format Online
Article
Text
id pubmed-9009454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Particle Therapy Co-operative Group
record_format MEDLINE/PubMed
spelling pubmed-90094542022-05-05 Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy Bao, Alicia Barsky, Andrew R. Maxwell, Russell Bekelman, Justin E. Both, Stefan Christodouleas, John P. Deville, Curtiland Fang, Penny Tochner, Zelig A. Vapiwala, Neha Int J Part Ther Original Articles PURPOSE: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment. METHODS: One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS. RESULTS: The median length of follow-up was 8.3 years (range, 1.2–10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P > .05). CONCLUSION: Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies. The Particle Therapy Co-operative Group 2021-10-20 /pmc/articles/PMC9009454/ /pubmed/35530185 http://dx.doi.org/10.14338/IJPT-21-00016 Text en ©Copyright 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/Distributed under Creative Commons CC-BY. Open Access
spellingShingle Original Articles
Bao, Alicia
Barsky, Andrew R.
Maxwell, Russell
Bekelman, Justin E.
Both, Stefan
Christodouleas, John P.
Deville, Curtiland
Fang, Penny
Tochner, Zelig A.
Vapiwala, Neha
Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
title Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
title_full Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
title_fullStr Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
title_full_unstemmed Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
title_short Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
title_sort long-term clinical outcomes in favorable risk prostate cancer patients receiving proton beam therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009454/
https://www.ncbi.nlm.nih.gov/pubmed/35530185
http://dx.doi.org/10.14338/IJPT-21-00016
work_keys_str_mv AT baoalicia longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT barskyandrewr longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT maxwellrussell longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT bekelmanjustine longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT bothstefan longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT christodouleasjohnp longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT devillecurtiland longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT fangpenny longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT tochnerzeliga longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy
AT vapiwalaneha longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy